Literature DB >> 23840126

Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations.

Jia-Hong Yang1, Hao Zhang, Xue-Bing Chen, Gao Chen, Xiu Wang.   

Abstract

AIM: To investigate the relationship between hepatitis B virus (HBV) genotype with spontaneous YMDD mutations and hepatocellular carcinoma (HCC) in HBV-related cirrhosis.
METHODS: We investigated 264 liver cirrhosis patients who were not treated with antiviral drugs, including 81 patients with HCC. YMDD mutations were detected by fluorescent hybridization bioprobe polymerase chain reaction (PCR) and melting curve assay using the Diagnosis Kit for HBV YMDD Mutation. Serum HBV genotypes were detected by real-time PCR using genotype-specific TaqMan probes. Statistical analysis was performed according to data type using the t test, χ(2) test and unconditional logistic regression analysis.
RESULTS: In the HCC group, genotype C strains, spontaneous YMDD mutations, and genotype C strains with YMDD mutations were detected in 33 (40.74%), 13 (16.05%) and 11 (13.58%) patients, respectively. In the liver cirrhosis (LC) group, HBV genotype C strains, spontaneous YMDD mutations, and genotype C strains with YMDD mutations were detected in 33 (18.03%), 7 (3.83%) and 2 (1.09%) patients, respectively. The differences in genotype C strains, spontaneous YMDD mutations, and genotype C strains with YMDD mutations between the two groups were statistically significant (χ(2) = 15.441, P = 0.000; χ(2) = 11.983, P = 0.001; P = 0.000). In the HCC and LC groups, there were seven patients infected by genotype B strains with YMDD mutations and 13 by genotype C strains with YMDD mutations. Further research revealed that HCC occurred in 2 patients infected by genotype B strains with YMDD mutations and 11 infected by genotype C strains with YMDD mutations. The difference was statistically significant (P = 0.000). Unconditional logistic regression analysis revealed that patients infected by genotype C strains with spontaneous YMDD mutations had a 7.775-fold higher risk for the development of HBV-related HCC than patients infected by other type HBV strains (P = 0.013, 95%CI: 1.540-39.264).
CONCLUSION: Genotype C strains with spontaneous YMDD mutations are an independent risk factor for HCC in LC patients and are important for early warning of HCC.

Entities:  

Keywords:  Hepatitis B virus; Hepatitis B virus genotype; Liver cirrhosis; Primary hepatocellular carcinoma; YMDD mutation

Mesh:

Substances:

Year:  2013        PMID: 23840126      PMCID: PMC3699046          DOI: 10.3748/wjg.v19.i24.3861

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

Review 1.  Epidemiology of hepatitis B in Europe and worldwide.

Authors:  Miriam J Alter
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

Review 2.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

3.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.

Authors:  Y F Liaw; R N Chien; C T Yeh; S L Tsai; C M Chu
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

4.  Epidemiological and clinical features of hepatitis B virus related liver failure in China.

Authors:  Chen Liu; Yu-Ming Wang; Ke Fan
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

Review 5.  Hepatitis B virus infection and the risk of hepatocellular carcinoma.

Authors:  Ya-Jun Tan
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

6.  No benefit to continue lamivudine therapy after emergence of YMDD mutations.

Authors:  Yun-Fan Liaw; Rong-Non Chien; Chau-Ting Yeh
Journal:  Antivir Ther       Date:  2004-04

7.  Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.

Authors:  Marie Matsuda; Fumitaka Suzuki; Yoshiyuki Suzuki; Akihito Tsubota; Norio Akuta; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Junko Satoh; Kimiko Takagi; Mariko Kobayashi; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2004-01       Impact factor: 7.527

8.  Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China.

Authors:  Xiaofeng Liang; Shengli Bi; Weizhong Yang; Longde Wang; Gang Cui; Fuqiang Cui; Yong Zhang; Jianhua Liu; Xiaohong Gong; Yuansheng Chen; Fuzhen Wang; Hui Zheng; Feng Wang; Jing Guo; Zhiyuan Jia; Jingchen Ma; Huaqing Wang; Huiming Luo; Li Li; Shuigao Jin; Stephen C Hadler; Yu Wang
Journal:  J Infect Dis       Date:  2009-07-01       Impact factor: 5.226

9.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

Authors:  Xiaofeng Liang; Shengli Bi; Weizhong Yang; Longde Wang; Gang Cui; Fuqiang Cui; Yong Zhang; Jianhua Liu; Xiaohong Gong; Yuansheng Chen; Fuzhen Wang; Hui Zheng; Feng Wang; Jing Guo; Zhiyuan Jia; Jingchen Ma; Huaqing Wang; Huiming Luo; Li Li; Shuigao Jin; Stephen C Hadler; Yu Wang
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641

10.  Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.

Authors:  Hwai-I Yang; Shiou-Hwei Yeh; Pei-Jer Chen; Uchenna H Iloeje; Chin-Lan Jen; Jun Su; Li-Yu Wang; Sheng-Nan Lu; San-Lin You; Ding-Shinn Chen; Yun-Fan Liaw; Chien-Jen Chen
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

View more
  10 in total

Review 1.  Overview of hepatitis B virus mutations and their implications in the management of infection.

Authors:  Patrizia Caligiuri; Rita Cerruti; Giancarlo Icardi; Bianca Bruzzone
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.

Authors:  You-Wen Tan; Yun Ye; Guo-Hong Ge; Wei Zhao; Jian-He Gan; Yun Zhao; Zhi-Lin Niu; Dong-Jun Zhang; Li Chen; Xue-Jun Yu; Li-Jun Yang
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

3.  Von Hippel-Lindau gene single nucleotide polymorphism (rs1642742) may be related to the occurrence and metastasis of HBV-related hepatocellular carcinoma.

Authors:  Xuebing Chen; Hao Zhang; Shimei Ou; Huijuan Chen
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

Review 4.  Hepatitis B virus genetic mutations and evolution in liver diseases.

Authors:  Tao Shen; Xin-Min Yan
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

5.  Distribution and epidemiologic trends of HBV genotypes and subtypes in 14 countries neighboring china.

Authors:  Zhao Qian; Wang Jianqiong; Li Hongmei; Zeng Rong; Li Li; Zhang Jinping; Shen Tao
Journal:  Hepat Mon       Date:  2015-05-23       Impact factor: 0.660

6.  Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.

Authors:  Ya Fu; Yongbin Zeng; Tianbin Chen; Huijuan Chen; Ni Lin; Jinpiao Lin; Xiaofeng Liu; Er Huang; Songhang Wu; Shu Wu; Siyi Xu; Long Wang; Qishui Ou
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

7.  Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus.

Authors:  Hongcan Liu; Zemin Wan; Lanhui She; Yajuan Zhu; Zhiliang Cai; Bin Wu; Qizhen Zhuang; Peifeng Ke; Xinzhong Wu; Zhuo Li; Xianzhang Huang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 8.  The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis.

Authors:  Min He; Yu Wu; Mengmeng Wang; Wenwen Chen; Weian Yuan; Jian Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-05       Impact factor: 2.629

9.  A novel complex A/C/G intergenotypic recombinant of hepatitis B virus isolated in southern China.

Authors:  Heling Su; Yan Liu; Zhihui Xu; Shuquan Cheng; Haiyan Ye; Qing Xu; Qingbo Liu; Shuhong Tan; Dongping Xu; Yongming Liu
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

10.  Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine.

Authors:  I-Cheng Lu; Mei-Chu Yen Jean; Chi-Wei Lin; Wei-Hung Chen; Daw-Shyong Perng; Chih-Wen Lin; Hung-Yi Chuang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.